About Transdermal Drug Delivery
Transdermal drug delivery is a large and growing vertical market of the Pharmaceutical industry. Transdermal drug delivery is defined as a system that utilizes skin as a site for continuous drug administration into the systemic circulation. Several methods of transdermal drug delivery include plasters, various ointments and, most commonly, patches. Transdermal drug administration has several advantages. First, the method of delivery is non-invasive, which is much less traumatic to the patient as compared to other forms of drug delivery. Also, it can be effective in assuring that a patient receives a full dosage of a drug and helps in increasing the compliance rate. However, there are difficulties associated with administering medication through the skin. The natural function of the skin is to act as a protective barrier, so it is often the case that drugs are not chemically suitable to penetrating the skin.
TechNavio's analysts forecast the Global Transdermal Drug Delivery market will grow at a CAGR of 9.92 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Transdermal Drug Delivery market for the period 2013–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs administered transdermally and proprietary transdermal technologies available in the market. The Global Transdermal Drug Delivery market can be divided into five segments: Smoking Cessation, Pain Management, Hormone Therapy, Cardiovascular Indications, and Others.
TechNavio's report, the Global Transdermal Drug Delivery Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Transdermal Drug Delivery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• ANI Pharmaceuticals Inc.
• Antares Pharma Inc.
• Bayer AG
• Janssen Pharmaceuticals Inc.
• Novartis AG
Other Prominent Vendors
• 3M Pharmaceuticals Co.
• Durect Corp.
• Iontera Inc.
• Isis Biopolymer Inc.
• LTS Lohmann Therapie-Systeme AG
• Mylan Laboratories Inc.
• Nitto Denko Corp.
• Pantec Biosolutions AG
•
• Phosphagenics Ltd.
• Tesa Labtec GmbH
• Teva Pharmaceutical Industries Ltd.
Key Market Driver
• Increase in Number of Transdermal Drug Delivery Products
• For a full, detailed list, view our report
Key Market Challenge
• Availability of Alternatives
• For a full, detailed list, view our report
Key Market Trend
• Increase in R&D Activities
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Competitive Assessment of Transdermal Drugs Delivery Market
08. Optimisation of Transdermal Drug Delivery
09. Market Segmentation by Application
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 ANI Pharmaceuticals Inc.
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Business Segmentation
19.1.5 Business Segmentation by Revenue 2013
19.1.6 Business Segmentation by Revenue 2012 and 2013
19.1.7 Key Developments
19.1.8 SWOT Analysis
19.1.9 Strengths
19.1.10 Weaknesses
19.1.11 Opportunities
19.1.12 Threats
19.2 Antares Pharma Inc.
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Strategy
19.2.5 Segmentation by Products
19.2.6 Key Information
19.2.7 SWOT Analysis
19.2.8 Strengths
19.2.9 Weaknesses
19.2.10 Opportunities
19.2.11 Threats
19.3 Bayer AG
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Business Strategy
19.3.5 Sales Segmentation by Business
19.3.6 Sales by Geographical Segmentation
19.3.7 Key Information
19.3.8 SWOT Analysis
19.3.9 Strengths
19.3.10 Weaknesses
19.3.11 Opportunities
19.3.12 Threats
19.4 Janssen Pharmaceuticals Inc.
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation
19.4.4 Business Strategy
19.4.5 Key Developments
19.4.6 SWOT Analysis
19.4.7 Strengths
19.4.8 Weaknesses
19.4.9 Opportunities
19.4.10 Threats
19.5 Novartis AG
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Sales by Geography
19.5.6 Business Strategy
19.5.7 Key Developments
19.5.8 SWOT Analysis
19.5.9 Strengths
19.5.10 Weaknesses
19.5.11 Opportunities
19.5.12 Threats
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Transdermal Drug Delivery Market 2013-2018 (US$ billion)
Exhibit 3: Global Transdermal Drug Delivery Market by Application
Exhibit 4: Global Transdermal Drug Delivery Market Segmentation 2013
Exhibit 5: Global Transdermal Drug Delivery Market by Geographical Segmentation
Exhibit 6: ANI Pharmaceuticals Inc.: Business Segmentation 2013
Exhibit 7: ANI Pharmaceuticals Inc.: Business Segmentation by Revenue 2013
Exhibit 8: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 9: Business Segmentation of Anatres Pharma, Inc. (2013)
Exhibit 10: Segmentation of Pipeline Products of Antares Pharma Inc. (2013)
Exhibit 11: Segmentation of Marketed Products of Antares Pharma Inc. (2013)
Exhibit 12: Business Segmentation of Bayer AG 2013
Exhibit 13: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 14: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 15: Janssen Pharmaceuticals Inc.: Product Segmentation 2013
Exhibit 16: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 17: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 18: Novartis AG: Sales by Geography 2013
